Challenges in Oral Immunotherapy

Abstract

Whereas avoidance remains a standard of food allergy management, US Food and Drug Administration approvals of a peanut oral immunotherapy product and the injected anti-IgE biologic omalizumab for food allergy give patients more treatment options than ever before. Here, we review a case that highlights the nuances in shared decision-making for finding the best treatment option for food allergy therapy and demonstrates the difficulty of approaching treatment side effects.